Abstract:Simin Liu, 1, 2 Xiu Zhou, 1, 2 Huiying Jie, 1, 2 Zetong Zheng, 1, 2 Bing Cai, 1, 2 Qingyun Mai, 1– 3 Canquan Zhou 1– 3 1 Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; 2 Guangdong Provincial Key Laboratory of Reproductive Medicine, Guangzhou, People's Republic of China; 3 Guangdong Provincial Clinical Research Center for Obstetrical and Gynecological Diseases, Guangzhou, People's Republic of China Correspondence: Canquan Zhou, Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-Sen University, No. 1 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China, Fax +86 87330736, Email Purpose: To determine the impact of polycystic ovary syndrome on in vitro fertilization/intracytoplasmic sperm injection and embryo transfer outcomes while analyzing the influencing factors. Patients and Methods: A retrospective cohort study comprised 4839 patients who underwent their first cycle of IVF/ICSI treatment from January 2016 to December 2021. Cumulative pregnancy rates, cumulative live birth rates, and late miscarriage rates compared between the PCOS group and control group. Subgroup analysis and binary regression were used to analyze the influence of BMI on clinical outcomes among individuals diagnosed with PCOS. Results: Non-obese PCOS patients exhibited higher cumulative pregnancy rates, cumulative live birth rates, and late miscarriage rates compared to the control group with the normal BMI population (84.7% vs71.2%, P < 0.001; 74.1% vs 61.6%, P < 0.001; 4.1% vs 2.0%, P = 0.002), but there was no significant difference in early miscarriage rates between the two groups. Conclusion: Non-obese PCOS patients demonstrated a notably higher cumulative live birth rate but also a higher risk of late miscarriage compared to non-PCOS females with a normal BMI. Keywords: body mass index, cumulative live birth rate, in vitro fertilization, intracytoplasmic sperm injection, late miscarriage, polycystic ovary syndrome Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder characterized primarily by a combination of clinical features, including hyperandrogenism, anovulation, and the presence of polycystic ovaries. 1 The intricate physiopathology of PCOS remains elusive, with the complexity attributed to the intricate interplay of components, including genetic predisposition, neuroendocrine dysfunction, prenatal influences, and lifestyle factors. 2–5 The global prevalence of PCOS among women of childbearing age varies, ranging from 6% to 21%. 6–9 PCOS represents a significant contributor to ovulatory infertility, carrying substantial implications for those affected by the condition. 10,11 Additionally, PCOS frequently coexists with metabolic disorders such as obesity, hyperlipidemia, insulin resistance, further complicating its clinical landscape. 12,13 Assisted Reproductive Technology (ART), which includes approaches such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), presents promising prospects for PCOS patients aiming to overcome their fertility challenges. 11,14 The Cumulative Live Birth Rate (CLBR), a metric that considers outcomes from both fresh embryo transfer cycles and frozen embryo transfer (FET) cycles, provides a more comprehensive measure for assessing the overall success of IVF/ICSI interventions. 15,16 The substantial response observed during ovarian stimulation in PCOS women contributes to an impressive CLBR of approximately 70%. 17 It is crucial to acknowledge that although PCOS patients may exhibit enhanced reproductive capacity, the presence of underlying metabolic disorders underscores the potential for an increased vulnerability to pregnancy complications and adverse perinatal outcomes. 18–21 While approximately 40–60% of PCOS patients are overweight or obese, 22,23 a clinically significant subset maintains a normal body mass index (BMI < 25 kg/m2). 24 These metabolic abnormalities extend beyond overweight or obese individuals with PCOS, impacting even those with a normal BMI. 25 Research has emphasized the adverse impact of obesity on IVF outcomes, including live birth rates and the risk of miscarriage. 26 However, there remains a notable scarcity of dedicated investigations specifically aimed at exploring the clinical outcomes of IVF/ICSI in individuals diagnosed with non-obese PCOS. Accordingly, we conducted a comprehensive evaluation of the clinical outcomes among a cohort of PCOS patients under -Abstract Truncated-

Effects of Dyslipidemia on In-Vitro Fertilization/intracytoplasmic Sperm Injection (IVF/ICSI) Pregnancy Outcome in Patients with Polycystic Ovary Syndrome(pcos)

Effect of hyperlipidemia on the outcome of in vitro fertilization in non-obese patients with polycystic ovary syndrome

A Comparison of the Miscarriage Rate Between Women with and Without Polycystic Ovarian Syndrome Undergoing IVF Treatment

The Effect of BMI and Lipid Metabolism on Pregnancy Outcomes of PCOS Patients Treated with ICSI_IVF

Adiposity and lipid metabolism indicators mediate the adverse effect of glucose metabolism indicators on oogenesis and embryogenesis in PCOS women undergoing IVF/ICSI cycles

P-610 Lipid Metabolism Mediated the Effect of Glucose Homeostasis and Insulin Resistance on IVF/ICSI Outcomes in PCOS Women

Serum Steroid Metabolome on the Day of Oocyte Retrieval in Women with Polycystic Ovarian Syndrome and Its Association with Pregnancy Outcome of in Vitro Fertilization.

Effect of Overweight/obesity on IVF-ET Outcomes in Chinese Patients with Polycystic Ovary Syndrome.

Lipid Metabolism Was Associated With Oocyte in vitro Maturation in Women With Polycystic Ovarian Syndrome Undergoing Unstimulated Natural Cycle

[Effect of baseline LH/FSH ratio in PCOS on IVF-ET outcomes: a retrospective cohort study]

Influencing of serum inflammatory factors on IVF/ICSI outcomes among PCOS patients with different BMI

Central Obesity Had Adverse Effect on in Vitro Fertilization Treatment in Women with Polycystic Ovary Syndrome

Correlation analysis of BMI with ovulation effect and clinical pregnancy rate in patients with polycystic ovary syndrome

Pregnancy Outcomes of Women With Polycystic Ovary Syndrome for the First In Vitro Fertilization Treatment: A Retrospective Cohort Study With 7678 Patients

Pregnancy Outcomes of Patients with Polycystic Ovary Syndrome Undergoing in Vitro Fertilization and Embryo Transfer

Higher Cumulative Live Birth Rate but Also Higher Late Miscarriage Risk in Non-Obese Women with Polycystic Ovary Syndrome Undergoing the First IVF/ICSI Cycle

[Effect of Dyslipidemia on Clinical Outcome of Infertility Patients Receiving Donor Eggs].

Analysis of the influencing factors of embryo quality and pregnancy outcomes in frozen-thawed embryo transfer cycle in polycystic ovary syndrome patients

Impact of Obesity on Endometrial Blood Flow in Women Without Polycystic Ovarian Syndrome During Intracytoplasmic Sperm Injection

Independent and Joint Effects of Β-Cell Dysfunction and Insulin Resistance on Reproductive Outcomes of IVF Cycles in Infertile PCOS Patients

Inflammation Mediates the Effect of Adiposity and Lipid Metabolism Indicators on the Embryogenesis of PCOS Women Undergoing in Vitro Fertilization/intracytoplasmic Sperm Injection.